Associated skeletal manifestations have been shown to improve after controlling the serum PTH concentration [33], likely by mitigating the bone high turnover process (i.e., osteitis fibrosa) and improving the bone mineral density [34]; however, the extraskeletal complications did not improve [35]. This evidence concerns the gene PTH and osteitis fibrosa.